ARTICLE | Clinical News
Synovir thalidomide: Began a Phase II trial
October 3, 1994 7:00 AM UTC
Celgene Corp. (CELG), Warren, N.J. Product: Synovir thalidomide, inhibitor of tumor necrosis factor alpha Indication: Cachexia (wasting) in AIDS Status: Began a Phase II trial testing two doses in 7...